Equity Research, Broker Reports, and media content on Poolbeg Pharma PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Poolbeg Pharma PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Poolbeg Pharma PLC

Company Profile

  • Profile:
  • Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Poolbeg Pharma PLC. We currently have 68 research reports from 4 professional analysts.

Date Source Announcement
30Nov23 07:00 RNS Poolbeg Pharma PLC - Directorate Change
21Nov23 07:00 RNS Poolbeg Pharma PLC - Immunomodulator II patent granted in Japan
16Nov23 07:00 RNS Poolbeg Pharma PLC - POLB 001 LPS Trial Data to be Presented at IUIS
09Nov23 07:00 RNS Poolbeg Pharma PLC - Former Amryt Pharma Leadership Team join Poolbeg
03Nov23 07:05 RNS Poolbeg Pharma PLC - POLB001 Data to be Presented at ASH Annual Meeting
01Nov23 07:00 RNS Poolbeg Pharma PLC - POLB 001 Oncology Programme Update Meeting
26Oct23 07:00 RNS Poolbeg Pharma PLC - SAB Endorses Influenza Drug Targets
  • Frequency of research reports


  • Research reports on

    Poolbeg Pharma PLC

  • Providers covering

    Poolbeg Pharma PLC